Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma ventures...

    Natco Pharma ventures into agrichemical space, sets up Rs 100 crore facility in AP

    Farhat NasimWritten by Farhat Nasim Published On 2019-01-25T14:30:33+05:30  |  Updated On 25 Jan 2019 9:00 AM GMT
    Natco Pharma ventures into agrichemical space, sets up Rs 100 crore facility in AP

    Natco Pharma Ltd was incorporated in Hyderabad in 1981 with an initial investment of about US$ 54,954.


    Hyderabad: Nacto Pharma Limited on Friday said it is foraying into agrichemical space and initiated work on it green-field manufacturing facilities for producing niche products in that area in Nellore District of Andhra Pradesh.


    According to a press release issued by the city-based drug maker, the facility will manufacture both agrichemical technical and formulation products.


    “Natco strongly believes that its pharma strength in chemistry coupled with an acumen towards the selection of niche molecules would differentiate itself in the agrichemical space as well,” it said.


    Natco expects the facilities to be commissioned by the end of 2019 with a total capital expenditure of Rs 100 crore.


    Natco Pharma Ltd was incorporated in Hyderabad in 1981 with an initial investment of about US$ 54,954.


    Also Read: Natco Pharma Q2 Profit up 35 per cent to Rs 583 Crore

    agrichemical Andhra Pradesh AP news capital expenditure drugmaker formulation product Hyderabad Natco Natco pharma pharma news pharma news in india pharmacy news 
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

      Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

      Wellthy Therapeutics announces Rs 30 crore financing round led by Saama Capital

      Wellthy Therapeutics announces Rs 30 crore financing round led by Saama Capital

      Lasa Supergenerics gets FDA nod for Progesterone

      Lasa Supergenerics gets FDA nod for Progesterone

      SMS Pharma updates against USFDA statement on Ranitidine

      SMS Pharma updates against USFDA statement on Ranitidine

      Lupin Contributes Rs 21 crores in battle against COVID-19

      Lupin Contributes Rs 21 crores in battle against COVID-19

      AstraZeneca gets USFDA nod for Koselugo for paediatric patients with neurofibromatosis type 1

      AstraZeneca gets USFDA nod for Koselugo for paediatric patients with neurofibromatosis type 1

      KKRs Envision Healthcare hires bank to explore debt restructuring: Report

      KKR's Envision Healthcare hires bank to explore debt restructuring: Report

      Pfizer clinches coronavirus vaccine deal with German drugmaker, sees potential in antiviral treatment

      Pfizer clinches coronavirus vaccine deal with German drugmaker, sees potential in antiviral...

      Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after COVID-19 infection

      Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung...

      GSK , Vir Biotechnology enter collaboration to find coronavirus solutions

      GSK , Vir Biotechnology enter collaboration to find coronavirus solutions

      India should become self-reliant in medical equipment, devices: Kasturirangan

      India should become self-reliant in medical equipment, devices: Kasturirangan

      Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb

      Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers...

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells Health Ministry

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells...

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X